Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED.

Aliment Pharmacol Ther. 2015 Mar;41(6):532-43. doi: 10.1111/apt.13096. Epub 2015 Jan 28.

2.

In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity.

Berglin L, Bergquist A, Johansson H, Glaumann H, Jorns C, Lunemann S, Wedemeyer H, Ellis EC, Björkström NK.

PLoS One. 2014 Aug 20;9(8):e105375. doi: 10.1371/journal.pone.0105375. eCollection 2014.

3.

[Toxic hepatitis most likely triggered by dalteparin].

Levinson P, Glaumann H, Söderberg M.

Lakartidningen. 2013 Jul 17-Aug 6;110(29-31):1348-9. Swedish. No abstract available.

PMID:
23980446
4.

The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Said K, Glaumann H, Björnstedt M, Bergquist A.

Dig Dis Sci. 2012 May;57(5):1163-70. doi: 10.1007/s10620-012-2089-4. Epub 2012 Feb 28.

PMID:
22370917
5.

Probable dalteparin-induced hepatotoxicity in a man with alpha-1-antitrypsin deficiency.

Levinson P, Glaumann H, Söderberg M.

J Clin Pharmacol. 2012 Nov;52(11):1764-7. doi: 10.1177/0091270011427301. Epub 2011 Dec 13. No abstract available.

PMID:
22167567
6.

Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis.

Söderberg C, Marmur J, Eckes K, Glaumann H, Sällberg M, Frelin L, Rosenberg P, Stål P, Hultcrantz R.

APMIS. 2011 Jul;119(7):412-20. doi: 10.1111/j.1600-0463.2011.02746.x. Epub 2011 Apr 25.

PMID:
21635548
7.

[Liver biopsy a superior diagnostic method...in certain cases].

Glaumann H.

Lakartidningen. 2010 May 26-Jun 1;107(21):1385-7. Review. Swedish. No abstract available.

PMID:
20645614
8.

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R.

Hepatology. 2010 Feb;51(2):595-602. doi: 10.1002/hep.23314.

PMID:
20014114
9.

Transitions between variant forms of primary biliary cirrhosis during long-term follow-up.

Lindgren S, Glaumann H, Almer S, Bergquist A, Björnsson E, Broomé U, Danielsson A, Lebrun B, Prytz H, Olsson R.

Eur J Intern Med. 2009 Jul;20(4):398-402. doi: 10.1016/j.ejim.2008.12.011. Epub 2009 Feb 1.

PMID:
19524182
10.

High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis.

Olsson R, Glaumann H, Almer S, Broomé U, Lebrun B, Bergquist A, Björnsson E, Prytz H, Danielsson A, Lindgren S.

Eur J Intern Med. 2009 Mar;20(2):190-6. doi: 10.1016/j.ejim.2008.06.004. Epub 2008 Oct 11.

PMID:
19327611
11.

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.

Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, Lindh G, Enquist R, Quist A.

J Viral Hepat. 2008 Sep;15(9):641-5. doi: 10.1111/j.1365-2893.2008.00999.x. Epub 2008 May 27.

PMID:
18507753
12.

Gallbladder disease in patients with primary sclerosing cholangitis.

Said K, Glaumann H, Bergquist A.

J Hepatol. 2008 Apr;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019. Epub 2008 Jan 2.

PMID:
18222013
13.

Primary sclerosing cholangitis can present with acute liver failure: Report of two cases.

Bergquist A, Glaumann H, Lindberg B, Broomé U.

J Hepatol. 2006 May;44(5):1005-8. Epub 2006 Feb 28.

PMID:
16551483
14.

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L, Brenndörfer ED, Ahlén G, Weiland M, Hultgren C, Alheim M, Glaumann H, Rozell B, Milich DR, Bode JG, Sällberg M.

Gut. 2006 Oct;55(10):1475-83. Epub 2006 Mar 9.

16.

Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

Broomé U, Glaumann H, Lindstöm E, Lööf L, Almer S, Prytz H, Sandberg-Gertzén H, Lindgren S, Fork FT, Järnerot G, Olsson R.

J Hepatol. 2002 May;36(5):586-9.

PMID:
11983440
17.

Obstructive jaundice results in increased liver expression of uncoupling protein 2 and intact skeletal muscle glucose metabolism in the rat.

Isaksson B, Rippe C, Simonoska R, Holm JE, Glaumann H, Segersvärd R, Larsson J, Erlanson-Albertsson C, Permert J.

Scand J Gastroenterol. 2002 Jan;37(1):104-11.

PMID:
11843026
18.

Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis.

Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP.

J Hepatol. 2001 Mar;34(3):360-5.

PMID:
11322195
19.
20.
21.

The GB virus C/hepatitis G virus replicates in hepatocytes without causing liver disease in healthy blood donors.

Halasz R, Sällberg M, Lundholm S, Andersson G, Lager B, Glaumann H, Weiland O.

J Infect Dis. 2000 Dec;182(6):1756-60. Epub 2000 Oct 18.

PMID:
11069249
22.

Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.

Wejstål R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sönnerbor A, Uhnoo I, Weiland O; Swedish Reference Group for Antiviral Therapy; Medical Products Agency.

Scand J Infect Dis. 2000;32(5):465-70. No abstract available.

PMID:
11055647
23.

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

Schvarcz R, Glaumann H, Reichard O, Weiland O.

J Viral Hepat. 1999 May;6(3):237-42.

PMID:
10607236
24.

[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].

Wejstål R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sönnerborg A, Uhnoo I, Weiland O.

Lakartidningen. 1999 Nov 3;96(44):4795-8, 4800. Swedish. No abstract available.

PMID:
10584541
25.

Natural history of liver disease in cystic fibrosis.

Lindblad A, Glaumann H, Strandvik B.

Hepatology. 1999 Nov;30(5):1151-8.

PMID:
10534335
26.

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.

Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O.

J Hepatol. 1999 May;30(5):783-7.

PMID:
10365802
27.
29.

Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients.

Ljungman P, Johansson N, Aschan J, Glaumann H, Lönnqvist B, Ringdén O, Sparrelid E, Sönnerborg A, Winiarski J, Gahrton G.

Blood. 1995 Aug 15;86(4):1614-8.

PMID:
7632971
30.

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.

Reichard O, Glaumann H, Frydén A, Norkrans G, Schvarcz R, Sönnerborg A, Yun ZB, Weiland O.

Hepatology. 1995 Apr;21(4):918-22.

PMID:
7705800
31.

Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.

Reichard O, Glaumann H, Norkrans G, Wejstål R, Fryden A, Schvarcz R, Weiland O.

Liver. 1994 Aug;14(4):169-74.

PMID:
7526108
32.

Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm.

Broomé U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hultcrantz R.

Gut. 1994 Jan;35(1):84-9.

33.

Ontogeny of a human polychlorinated biphenyl-binding protein. Level of expression in tracheal aspirates in bronchopulmonary dysplasia.

Anderson O, Noack G, Robertson B, Glaumann H, Sonnenfeld T, Lund J.

Chest. 1994 Jan;105(1):17-22.

PMID:
8275728
34.

Pentamidine accumulates in rat liver lysosomes and inhibits phospholipid degradation.

Glaumann H, Bronner U, Ericsson O, Gustafsson LL, Rombo L.

Pharmacol Toxicol. 1994 Jan;74(1):17-22.

PMID:
8159632
35.
36.

Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis.

Schvarcz R, Glaumann H, Weiland O.

J Hepatol. 1993 Apr;18(1):15-23.

PMID:
7688011
37.

Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liver.

Glaumann H, Motakefi AM, Jansson H.

Liver. 1992 Aug;12(4 Pt 1):183-90.

PMID:
1406082
38.

Protracted cholestasis probably induced by oral contraceptive.

Wedén M, Glaumann H, Einarsson K.

J Intern Med. 1992 May;231(5):561-5.

PMID:
1602295
39.

Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Wejstål R, Norkrans G, Weiland O, Schvarcz R, Fuchs D, Wachter H, Fryden A, Glaumann H.

Clin Exp Immunol. 1992 Mar;87(3):340-5.

40.

Acetone-regulated synthesis and degradation of cytochrome P450E1 and cytochrome P4502B1 in rat liver [corrected].

Ronis MJ, Johansson I, Hultenby K, Lagercrantz J, Glaumann H, Ingelman-Sundberg M.

Eur J Biochem. 1991 Jun 1;198(2):383-9. Erratum in: Eur J Biochem 1991 Sep 15;200(3):812.

41.

[Chronic hepatitis: current diagnostics and treatment in different etiologic factors].

Glaumann H, Lööf L, Weiland O.

Lakartidningen. 1991 Mar 27;88(13):1201-4. Review. Swedish. No abstract available.

PMID:
1901930
42.

Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A.

Liver. 1991 Feb;11(1):30-8.

PMID:
1646369
43.

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A.

Scand J Infect Dis. 1991;23(4):413-20.

PMID:
1957127
44.

Proteolysis in isolated autophagic vacuoles from the rat pancreas. Effects of chloroquine administration.

Yucel-Lindberg T, Jansson H, Glaumann H.

Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;61(2):141-5.

PMID:
1683722
46.
47.

Liver damage in juvenile inflammatory bowel disease.

Nemeth A, Ejderhamn J, Glaumann H, Strandvik B.

Liver. 1990 Aug;10(4):239-48.

PMID:
2215095
48.
49.

Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis.

Broomé U, Glaumann H, Hultcrantz R, Forsum U.

Scand J Gastroenterol. 1990 Jan;25(1):54-8.

PMID:
2406888

Supplemental Content

Loading ...
Support Center